Skip to main content

REVIEW article

Front. Oncol.
Sec. Hematologic Malignancies
Volume 14 - 2024 | doi: 10.3389/fonc.2024.1400461
This article is part of the Research Topic Updates on the Management of Hematologic Malignancies from SOHO Italy: Educational Insights and Clinical Perspectives View all 4 articles

Novel insights and therapeutic approaches in Secondary AML

Provisionally accepted
Giovanni Marconi Giovanni Marconi 1*Michela Rondoni Michela Rondoni 2Beatrice Anna Zannetti Beatrice Anna Zannetti 2Irene Zacheo Irene Zacheo 3Davide Nappi Davide Nappi 3Agnese Mattei Agnese Mattei 3Serena Rocchi Serena Rocchi 2Francesco Lanza Francesco Lanza 1
  • 1 University of Bologna, Bologna, Italy
  • 2 Independent researcher, Ravenna, Italy
  • 3 IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', Meldola, Italy, Meldola, Italy

The final, formatted version of the article will be published soon.

    Secondary acute myeloid leukemia (sAML) presents as a complex and multifaceted ensamble of disorders, positioning itself as both a challenge and an intriguing frontier within hematologic oncology. Its origins are diverse, stemming from antecedent hematologic conditions, germline predisposing mutations, or the sequelae of cytotoxic therapies, and its development is driven by intricate genetic and epigenetic modifications. This complexity necessitates a diverse array of therapeutic strategies, each meticulously tailored to address the distinctive challenges sAML introduces. Such strategies require a personalized approach, considering the variegated clinical backgrounds of patients and the inherent intricacies of the disease. Allogeneic stem cell transplantation stands as a cornerstone, offering the potential for curative outcomes. This is complemented by the emergence of innovative treatments such as CPX-351, venetoclax, and glasdegib, which have demonstrated promising results in enhancing prognosis. The evolving landscape of sAML treatment underscores the importance of continued research and innovation in the field, aiming not only to improve patient outcomes but also to deepen our understanding of the disease's biological underpinnings, thereby illuminating pathways toward more effective and individualized therapies.

    Keywords: Acute Myeloid Leukemia, AML, Secondary AML, Myelodysplasia-related, Chemotherapy-related, AML Genetics, novel therapies

    Received: 13 Mar 2024; Accepted: 05 Jul 2024.

    Copyright: © 2024 Marconi, Rondoni, Zannetti, Zacheo, Nappi, Mattei, Rocchi and Lanza. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Giovanni Marconi, University of Bologna, Bologna, Italy

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.